98%
921
2 minutes
20
When marked for degradation, surface receptor and transporter proteins are internalized and delivered to endosomes where they are packaged into intralumenal vesicles (ILVs). Many rounds of ILV formation create multivesicular bodies (MVBs) that fuse with lysosomes exposing ILVs to hydrolases for catabolism. Despite being critical for protein degradation, the molecular underpinnings of MVB-lysosome fusion remain unclear, although machinery underlying other lysosome fusion events is implicated. But how then is specificity conferred? And how is MVB maturation and fusion coordinated for efficient protein degradation? To address these questions, we developed a cell-free MVB-lysosome fusion assay using Saccharomyces cerevisiae as a model. After confirming that the Rab7 ortholog Ypt7 and the multisubunit tethering complex HOPS (homotypic fusion and vacuole protein sorting complex) are required, we found that the Qa-SNARE Pep12 distinguishes this event from homotypic lysosome fusion. Mutations that impair MVB maturation block fusion by preventing Ypt7 activation, confirming that a Rab-cascade mechanism harmonizes MVB maturation with lysosome fusion.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/tra.12543 | DOI Listing |
Spectrochim Acta A Mol Biomol Spectrosc
September 2025
College of Chemistry, Chemical Engineering and Material Science, Soochow University, No. 199 Ren'Ai Road, Suzhou 215123, China; Jiangsu Key Laboratory of Medical Optics, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Science, Suzhou 215163, China. Electronic address: g
The dynamic monitoring of cell death processes remains a significant challenge due to the scarcity of highly sensitive molecular tools. In this study, two hemicyanine-based probes (5a-5b) with D-π-A structures were developed for organelle-specific viscosity monitoring. Both probes exhibited correlation with the Förster-Hoffmann viscosity-dependent relationship (R > 0.
View Article and Find Full Text PDFProc Natl Acad Sci U S A
September 2025
School of Medicine, Chongqing University, Chongqing 400044, China.
Engineering functional exosomes represents a cutting-edge approach in biomedicine, holding the promise to transform targeted therapy. However, challenges such as achieving consistent modification and scalability have limited their wider adoption. Herein, we introduce a universal and effective strategy for engineering multifunctional exosomes through cell fusion.
View Article and Find Full Text PDFMicrobiol Spectr
September 2025
Department of Ophthalmology, Mason Eye Institute, University of Missouri School of Medicine, Columbia, Missouri, USA.
Unlabelled: Zika virus (ZIKV) is the lone member of Flavivirus family known to cause congenital glaucoma following exposure. The molecular mechanisms of ZIKV-induced glaucoma remain elusive, with no known therapeutic modalities. Autophagy plays a dual role in viral infections and glaucoma pathogenesis.
View Article and Find Full Text PDFInt J Biol Macromol
September 2025
State Key Laboratory of Biocatalysis and Enzyme Engineering, Hubei Key Laboratory of Industrial Biotechnology, School of Life Sciences, Hubei University, Wuhan 430062, PR China. Electronic address:
Engineered bacteria have emerged as a promising therapeutic strategy for tumor therapy by exploiting the unique features of the tumor microenvironment (TME). In this study, we developed a low-endotoxin Escherichia coli expression system to produce a fusion protein comprising the CXCL12 with the nanobody KN035 Hypoxia and immunosuppression drive the selective colonization of engineered bacteria in tumor tissues, minimizing host toxicity. Unlike conventional PD-L1 antibodies that merely block immune checkpoints, our CXCL12-KN035 fusion protein simultaneously targets the CXCR7 receptor and PD-L1 on tumor cells, inducing receptor internalization and subsequent lysosomal degradation of PD-L1.
View Article and Find Full Text PDFJ Control Release
September 2025
Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; MOE Joint International Research Laboratory of Pancreatic Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
Gemcitabine-based chemotherapy remains a cornerstone in pancreatic cancer treatment, yet its efficacy is hindered by poor bioavailability and adaptive resistance mechanisms, such as autophagy. In this study, we developed a hyaluronic acid (HA) modified zeolitic imidazolate framework-8 (ZIF-8) drug-repurposing nanoplatform (HA/ZIF-8@BPP/Gem) against pancreatic cancer through the co-delivery of the antitussive benproperine phosphate (BPP) and gemcitabine (Gem). Using cell lines, patient-derived xenograft models, and orthotopic tumor models, we demonstrated that BPP and Gem, rapidly released from the nanoplatform in the acidic tumor microenvironment, exhibited synergistic cytotoxicity without causing significant biochemical abnormalities or organ toxicity.
View Article and Find Full Text PDF